The good times roll for Roche earnings

Gibson, Jane
October 2006
ICIS Chemical Business;10/23/2006, Vol. 1 Issue 40, p10
Trade Publication
The article reports that Roche rolled has increased its earnings for the first nine months of 2006. The company, now focused purely on pharmaceuticals and diagnostics, expects the full year also to see double digit percentage sales increases. Roche chairman and CEO Franz Humer pointed to oncology medicines, ahead 41%, and flu vaccine Tamiflu, as major drivers in the pharmaceutical sector.


Related Articles

  • Roche enjoys bird flu lift. Chynoweth, Emma; Gibson, Jane // ICIS Chemical Business;2/12/2007, Vol. 2 Issue 53, p9 

    The article reports on the profits posted by pharmaceutical firm Roche in 2006. Total net income for 2006 rose by one-third to Swiss franc 9.2 bn. Sales rose by 17 percent in local currencies, on the back of exceptionally strong organic growth, to a record level of Swfr42bn. The company expects...

  • Roche flies on Tamiflu.  // Chemical Market Reporter;10/24/2005, Vol. 268 Issue 14, p6 

    Reports on the financial performance of Roche Group company in the third quarter of 2005. Total pharmaceutical revenues; Percentage on the increase in sales; Total sales.

  • Roche Has Other Options if Illumina Takeover Fails, Humer Says.  // MondayMorning;3/12/2012, Vol. 20 Issue 11, p1 

    The article reports on Switzerland-based Roche Holding AG's plan to takeover gene-mapping company Illumina Inc., San Diego, California. It informs about the rejection of Roche Holding's offer by Illumina because of its inadequacy. According to Franz Humer, chairman of Roche Holding, the company...

  • COMPANY SPOTLIGHT - Roche.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p45 

    Feature Roche Group, a research-based health care group active in the discovery, development and manufacture of pharmaceuticals and diagnostic systems. Financial performance in 2002; Business description; Key employees including Franz Humer, CEO, and Henri B. Meier, chief financial officer;...

  • Roche Group Is Back on the Growth Track.  // Chemical Market Reporter;8/20/2001, Vol. 260 Issue 8, p4 

    Reports on the financial growth of Roche Group based on the combined strength in diagnostics and pharmaceutical segments. Research and development efforts in the company's diagnostics and pharmaceutical segments; Performance of the North American pharmaceutical division; Actions taken by Roche...

  • The good times roll for Roche earnings.  // ICIS Chemical Business Americas;10/23/2006, Vol. 270 Issue 15, p13 

    The article focuses on the financial results of Swiss pharmaceutical company Roche for the first nine months of 2006. Roche's sales have totaled to $23.9 billion, an increase of approximately 19 percent or 17 percent based on Switzerland currencies. The company expects to see double digit...

  • Key Facts.  // Roche Group SWOT Analysis;Apr2007, p4 

    Key facts about Roche Holding Ltd., a holding company which is specialized in the discovery, development and commercialization of therapeutics for life-threatening diseases, are presented. Address and contact information is given, as well as statistics on revenues, financial year end data and...

  • Roche Chairman Steps Down.  // MondayMorning;3/11/2013, Vol. 21 Issue 9, p1 

    The article announces the resignation of Franz Humer from the post of Chairman at the Roche Holding AG.

  • DATAMONITOR: F. Hoffmann-La Roche Ltd.  // Roche Group SWOT Analysis;Jul2009, p1 

    The article presents a corporate profile for F. Hoffman-La Roche Ltd., one of the leading research-focused healthcare groups in the world. Roche is based in Basel, Switzerland which specializes in the discovery and commercialization of innovative diagnostic and therapeutic products. The company...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics